Brain 18 F-FDG PET reveals cortico-subcortical hypermetabolic dysfunction in juvenile neuropsychiatric systemic lupus erythematosus.
Children
Fluorodeoxyglucose
Hypermetabolism
Juvenile systemic lupus erythematosus
Neuropsychiatric systemic lupus erythematosus
Positron emission tomography
Statistical parametric mapping
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
10
11
2023
accepted:
02
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
2
4
2024
Statut:
epublish
Résumé
In juvenile systemic lupus erythematosus (j-SLE) with neuropsychiatric (NP) symptoms, there is a lack of diagnostic biomarkers. Thus, we study whether PET-FDG may identify any metabolic dysfunction in j-NPSLE. A total of 19 Patients exhibited mainly psychiatric symptoms, with diffuse inflammatory j-NPSLE. First PET (n = 11) was performed at a mean of 15y of age, second/third PET (n = 7/n = 1) 6 to 19 m later. PET individual analysis detected focal bilateral anomalies in 13/19 exams visually but 19/19 using spm (unc.), mostly hypermetabolic areas (18/19). A total of 15% of hypermetabolic areas identified by spm had been missed visually. PET group analysis (n = 19) did not identify any hypometabolic area, but a large bilateral cortico-subcortical hypermetabolic pattern including, by statistical decreasing order (unc.), thalamus, subthalamic brainstem, cerebellum (vermis and cortex), basal ganglia, visual, temporal and frontal cortices. Mostly the subcortical hypermetabolism survived to FWE analysis, being most intense and extensive (51% of total volume) in thalamus and subthalamus brainstem. Hypermetabolism was strictly subcortical in the most severe NP subgroup (n = 8, scores 2-3) whereas it also extended to cerebral cortex, mostly visual, in the less severe subgroup (n = 11, scores 0-1), but difference was not significant. Longitudinal visual analysis was inconclusive due to clinical heterogeneity. j-NPSLE patients showed a robust bilateral cortico-subcortical hypermetabolic network, focused subcortically, particularly in thalamus, proportionally to psychiatric features severity. Further studies with larger, but homogeneous, cohorts are needed to determine the sensitivity and specificity of this dysfunctional pattern as a potential biomarker in diffuse inflammatory j-NPSLE with normal brain MRI.
Sections du résumé
BACKGROUND
BACKGROUND
In juvenile systemic lupus erythematosus (j-SLE) with neuropsychiatric (NP) symptoms, there is a lack of diagnostic biomarkers. Thus, we study whether PET-FDG may identify any metabolic dysfunction in j-NPSLE.
METHODS
METHODS
A total of 19
RESULTS
RESULTS
Patients exhibited mainly psychiatric symptoms, with diffuse inflammatory j-NPSLE. First PET (n = 11) was performed at a mean of 15y of age, second/third PET (n = 7/n = 1) 6 to 19 m later. PET individual analysis detected focal bilateral anomalies in 13/19 exams visually but 19/19 using spm (unc.), mostly hypermetabolic areas (18/19). A total of 15% of hypermetabolic areas identified by spm had been missed visually. PET group analysis (n = 19) did not identify any hypometabolic area, but a large bilateral cortico-subcortical hypermetabolic pattern including, by statistical decreasing order (unc.), thalamus, subthalamic brainstem, cerebellum (vermis and cortex), basal ganglia, visual, temporal and frontal cortices. Mostly the subcortical hypermetabolism survived to FWE analysis, being most intense and extensive (51% of total volume) in thalamus and subthalamus brainstem. Hypermetabolism was strictly subcortical in the most severe NP subgroup (n = 8, scores 2-3) whereas it also extended to cerebral cortex, mostly visual, in the less severe subgroup (n = 11, scores 0-1), but difference was not significant. Longitudinal visual analysis was inconclusive due to clinical heterogeneity.
CONCLUSIONS
CONCLUSIONS
j-NPSLE patients showed a robust bilateral cortico-subcortical hypermetabolic network, focused subcortically, particularly in thalamus, proportionally to psychiatric features severity. Further studies with larger, but homogeneous, cohorts are needed to determine the sensitivity and specificity of this dysfunctional pattern as a potential biomarker in diffuse inflammatory j-NPSLE with normal brain MRI.
Identifiants
pubmed: 38564068
doi: 10.1186/s13550-024-01088-4
pii: 10.1186/s13550-024-01088-4
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34Informations de copyright
© 2024. The Author(s).
Références
Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014;13:1082–9.
doi: 10.1016/j.autrev.2014.08.034
pubmed: 25172239
Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol. 2019;15:137–52.
doi: 10.1038/s41584-018-0156-8
pubmed: 30659245
Govoni M, Hanly JG. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? Rheumatology (Oxford). 2020;59(Suppl 5):52–62.
doi: 10.1093/rheumatology/keaa404
Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:529–35.
doi: 10.1136/ard.2008.106351
pubmed: 19359262
Deijns SJ, Broen JCA, Kruyt ND, Schubart CD, Andreoli L, Tincani A, et al. The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: a narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines. Autoimmun Rev. 2020;19:102592.
doi: 10.1016/j.autrev.2020.102592
pubmed: 32561462
Labouret M, Costi S, Bondet V, Trebossen V, Le Roux E, Ntorkou A, et al. Juvenile neuropsychiatric systemic lupus erythematosus: identification of Novel Central Neuroinflammation biomarkers. J Clin Immunol. 2023;43:615–24.
doi: 10.1007/s10875-022-01407-1
pubmed: 36469191
Luyendijk J, Steens SC, Ouwendijk WJ, Steup-Beekman GM, Bollen EL, van der Grond J, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum. 2011;63:722–32.
doi: 10.1002/art.30157
pubmed: 21360502
Brendel M, Focke C, Blume T, Peters F, Deussing M, Probst F, et al. Time Courses of Cortical Glucose Metabolism and microglial activity across the Life Span of Wild-Type mice: a PET study. J Nucl Med. 2017;58:1984–90.
doi: 10.2967/jnumed.117.195107
pubmed: 28705919
Kello N, Anderson E, Diamond B. Cognitive dysfunction in systemic lupus erythematosus: a case for initiating trials. Arthritis Rheumatol. 2019;71:1413–25.
doi: 10.1002/art.40933
pubmed: 31102496
Turpin S, Martineau P, Levasseur MA, Meijer I, Décarie JC, Barsalou J, et al. 18F-Flurodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) findings in children with encephalitis and comparison to conventional imaging. Eur J Nucl Med Mol Imaging. 2019;46:1309–24.
doi: 10.1007/s00259-019-04302-x
pubmed: 30863933
Bordonne M, Chawki MB, Doyen M, Kas A, Guedj E, Tyvaert L, et al. Brain
doi: 10.1007/s00259-021-05299-y
pubmed: 33677643
Yin Y, Wu J, Wu S, Chen S, Cheng W, Li L, et al. Usefulness of brain FDG PET/CT imaging in pediatric patients with suspected autoimmune encephalitis from a prospective study. Eur J Nucl Med Mol Imaging. 2022;49:1918–29.
doi: 10.1007/s00259-021-05649-w
pubmed: 34939173
Komatsu N, Kodama K, Yamanouchi N, Okada S, Noda S, Nawata Y, et al. Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur Neurol. 1999;42:41–8.
doi: 10.1159/000008067
pubmed: 10394047
Weiner SM, Otte A, Schumacher M, Klein R, Gutfleisch J, Brink I, et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis. 2000;59:377–85.
doi: 10.1136/ard.59.5.377
pubmed: 10784521
Lee SW, Park MC, Lee SK, Park YB. The efficacy of brain (18)F-fluorodeoxyglucose positron emission tomography in neuropsychiatric lupus patients with normal brain magnetic resonance imaging findings. Lupus. 2012;21:1531–7.
doi: 10.1177/0961203312459104
pubmed: 22941565
Curiel R, Akin EA, Beaulieu G, DePalma L, Hashefi M. PET/CT imaging in systemic lupus erythematosus. Ann N Y Acad Sci. 2011;1228:71–80.
doi: 10.1111/j.1749-6632.2011.06076.x
pubmed: 21718325
Jorgensen A, Law I, Nielsen S, Jorgensen MB. Fluorodeoxyglucose positron emission tomography in juvenile systemic lupus erythematosus with psychiatric manifestations: relation to psychopathology and treatment response in two cases. Rheumatology. 2012;51:193–5. Letter to Editor.
doi: 10.1093/rheumatology/ker287
pubmed: 21984762
Soubrier C, Faucher B, Guedj E, Kaphan E, Ebbo M, De Sainte Mari B, et al. Brain 18F-fluorodeoxyglucose positron emission tomography/computed tomography detection of neuropsychiatric lupus with normal cerebral magnetic resonance imaging. Rheumatology. 2020;59:457. Clinical vignette.
doi: 10.1093/rheumatology/kez233
pubmed: 31209502
Archambaud F, Bouilleret V, Hertz-Pannier L, Chaumet-Riffaud P, Rodrigo S, Dulac O, et al. Optimizing statistical parametric mapping analysis of 18F-FDG PET in children. EJNMMI Res. 2013;3:2.
doi: 10.1186/2191-219X-3-2
pubmed: 23289862
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Étard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage. 2002;15:273–89.
doi: 10.1006/nimg.2001.0978
pubmed: 11771995
Mazzuca M, Jambaque I, Hertz-Pannier L, Bouilleret V, Archambaud F, Caviness V, et al. 18F-FDG PET reveals frontotemporal dysfunction in children with fever-induced refractory epileptic encephalopathy. J Nucl Med. 2011;52:40–7.
doi: 10.2967/jnumed.110.077214
pubmed: 21149491
Trotta N, Archambaud F, Goldman S, Baete K, Van Laere K, Wens V, et al. Functional integration changes in regional brain glucose metabolism from childhood to adulthood. Hum Brain Mapp. 2016;37:3017–30.
doi: 10.1002/hbm.23223
pubmed: 27133021
Ligot N, Archambaud F, Trotta N, Goldman S, Van Bogaert P, Chiron C, et al. Default mode network hypometabolism in epileptic encephalopathies with CSWS. Epilepsy Res. 2014;108:861–71.
doi: 10.1016/j.eplepsyres.2014.03.014
pubmed: 24746674
Krakauer M, Law I. FDG PET brain imaging in neuropsychiatric systemic lupus erythematosis with choreic symptoms. Clin Nucl Med. 2009;34:122–3.
doi: 10.1097/RLU.0b013e318192c4d2
pubmed: 19352272
Mackay M, Tang CC, Volpe BT, Aranow C, Mattis PJ, Korff RA, et al. Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Sci Med. 2015;2:e000074.
doi: 10.1136/lupus-2014-000074
pubmed: 25861456
Mackay M, Vo A, Tang CC, Small M, Anderson EW, Ploran EJ, et al. Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. JCI Insight. 2019;4:e124002.
doi: 10.1172/jci.insight.124002
pubmed: 30626758
Van Bogaert P, Wikler D, Damhaut P, Szliwowski HB, Goldman S. Regional changes in glucose metabolism during brain development from the age of 6 years. NeuroImage. 1998;8:62–8.
doi: 10.1006/nimg.1998.0346
pubmed: 9698576
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and
doi: 10.1016/S1474-4422(20)30314-8
pubmed: 33098804
Pardini M, Huey ED, Spina S, Kreisl WC, Morbelli S, Wassermann EM, et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology. 2019;92:e1121–35.
doi: 10.1212/WNL.0000000000007038
pubmed: 30700592
Pilotto A, Premi E, Paola Caminiti S, Presotto L, Turrone R, Alberici A, et al. Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology. 2018;90:e1029–37.
doi: 10.1212/WNL.0000000000005161
pubmed: 29453242
Iaccarino L, Sala A, Caminiti SP, Santangelo R, Iannaccone S, Magnani G, et al. The brain metabolic signature of visual hallucinations in dementia with Lewy bodies. Cortex. 2018;108:13–24.
doi: 10.1016/j.cortex.2018.06.014
pubmed: 30098477
Nishio Y, Yokoi K, Uchiyama M, Mamiya Y, Watanabe H, Gang M, et al. Deconstructing psychosis and misperception symptoms in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88:722–9.
doi: 10.1136/jnnp-2017-315741
pubmed: 28600444
Morningstar M, Hung A, Mattson WI, Gedela S, Ostendorf AP, Nelson EE. Internalizing symptoms in intractable pediatric epilepsy: structural and functional brain correlates. Epilepsy Behav. 2020;103:106845.
doi: 10.1016/j.yebeh.2019.106845
pubmed: 31882324
Huang YS, Liu FY, Lin CY, Hsiao IT, Guilleminault C. Brain imaging and cognition in young narcoleptic patients. Sleep Med. 2016;24:137–44.
doi: 10.1016/j.sleep.2015.11.023
pubmed: 27663355
Braun AR, Randolph C, Stoetter B, Mohr E, Cox C, Vladar K, et al. The functional neuroanatomy of Tourette’s syndrome: an FDG-PET study. II: relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology. 1995;13:151–68.
doi: 10.1016/0893-133X(95)00052-F
pubmed: 8597526
Shine JM, Lewis LD, Garrett DD, Hwang K. The impact of the human thalamus on brain-wide information processing. Nat Rev Neurosci. 2023;24(7):416–30.
doi: 10.1038/s41583-023-00701-0
pubmed: 37237103